| Date | Title | Description |
| 25.04.2025 | Rezolute, Inc. Announces Closing of Underwritten Offering | NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announ... |
| 31.01.2025 | Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference | REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unme... |
| 31.01.2025 | Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference | REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unme... |
| 05.12.2024 | Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unme... |
| 03.12.2024 | FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism | REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unme... |
| 07.11.2024 | Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update | Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications
Phase 3 sunRIZE study on track; U.S. enrollment expected to commen... |
| 05.11.2024 | Rezolute to Participate in Upcoming Investor Conferences | REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unme... |
| 19.09.2024 | Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update | FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first half of 2025
REDWOOD ... |
| 19.09.2024 | Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update | FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first half of 2025
REDWOOD ... |
| 27.08.2024 | Rezolute to Participate in Upcoming Investor Conferences | REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by h... |
| 05.08.2024 | Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism | Second rare disease program with RZ358 in Phase 3 development
Follows successful treatment of multiple patients with tumor hyperinsulinism
under the Company’s Expanded Access Program
REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- R... |
| 05.08.2024 | Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism | Second rare disease program with RZ358 in Phase 3 development
Follows successful treatment of multiple patients with tumor hyperinsulinism
under the Company’s Expanded Access Program
REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- R... |
| 31.07.2024 | Rezolute to Participate in the BTIG Virtual Biotechnology Conference | REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, t... |
| 27.06.2024 | Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement | NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announc... |
| 24.06.2024 | Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds | NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announc... |
| 14.06.2024 | Rezolute's Strategic Move: A $60 Million Public Offering to Transform Rare Disease Treatments | In a bold and calculated move, Rezolute, a renowned biopharmaceutical company, has announced a significant milestone with the pricing of a public offering totaling $60 million. This offering, a testament to Rezolute's commitment to developi... |
| 14.06.2024 | Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants | NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announc... |
| 13.06.2024 | Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announc... |
| 13.06.2024 | Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants | NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announc... |
| 15.05.2024 | Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update | Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Completed in-vivo toxicology study in brown Norway rats; early results sho... |
| 06.03.2024 | Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) | - |
| 11.05.2023 | Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress | The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
/EIN News/ -- REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company de... |
| 10.02.2023 | Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress | /EIN News/ -- Initiated Phase 2 proof-of-concept study of RZ402
Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023
REDWOOD CITY, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-s... |
| 20.10.2022 | Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting | REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devast... |
| 15.09.2022 | Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress | Announced a $130 million registered direct offering and concurrent private placement priced at-the-market
Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022
Phase 2 proof-of-concept study of RZ402 expec... |
| 07.09.2022 | Rezolute Announces Presentation at the 60th Annual ESPE Meeting | Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation
REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated ... |
| 12.05.2022 | Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress | Announced a $130 million registered direct offering and concurrent private placement
Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75%... |
| 04.05.2022 | Rezolute, Inc. Announces Closing of Registered Direct Offering | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| 04.05.2022 | Rezolute to Host Corporate Update Call on May 4, 2022 | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| 01.05.2022 | Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism | Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses
≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia
Study... |
| 01.05.2022 | Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market | REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for ... |
| 26.04.2022 | RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 | Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company ded... |
| 23.03.2022 | Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism | The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability
Results to be presented in an oral presentation at a medical congress in 2Q 2022
REDWOOD CITY, Calif., March 23, 2022 (GLOBE NEWSWI... |
| 19.04.2021 | Seagen gets August PDUFA for Padcev expansions; Adaptate pulls in new cash for gamma delta T cell antibodies | Seagen is riding the wave of two new priority reviews straight to the FDA.
The Bothell, WA-based biotech and their partners at Astellas announced Monday that two supplemental BLAs for Padcev had been accepted by US regula... |
| 19.04.2021 | REZOLUTE, INC.
Rezolute : Announces $30 Million Debt Financing Agreement with SLR Capital Partners | REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with ... |
